The ICAM1 Knockout CAL-27 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population of CAL-27 cells harboring a targeted disruption of the ICAM1 gene. This loss-of-function model is generated in a human tongue squamous cell carcinoma background and is supplied as a heterogeneous mixture of edited cells, enabling researchers to interrogate the functional consequences of ICAM1 ablation in a malignant epithelial context. The polyclonal format preserves the natural biological variability of the knockout pool, making it suitable for population-level studies of adhesion, migration, and immune interactions without the clonal artifacts associated with single-cell-derived lines.
CAL-27 is an established human oral squamous cell carcinoma cell line derived from a primary tongue lesion, widely employed as a model for head and neck cancer research. These adherent epithelial cells exhibit typical malignant features and have been extensively characterized in studies of tumor invasion, metastasis, and the oral tumor microenvironment. Their use as the host for ICAM1 knockout allows direct investigation of cell adhesion molecule function in a clinically relevant setting, as tongue squamous cell carcinoma is known to exhibit altered ICAM1 expression during disease progression.
ICAM1 (Intercellular Adhesion Molecule 1) is a transmembrane glycoprotein that functions as a counter-receptor for the leukocyte integrins LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18), and also interacts with fibrinogen and hyaluronan. Its expression is upregulated by pro-inflammatory stimuli, including TNF-??, IL-1??, and LPS, primarily through NF-??B-mediated transcriptional activation. Upon ligand engagement, ICAM1 triggers intracellular signaling cascades involving Src family kinases, RhoA GTPase, and the ERK1/2 MAPK pathway, thereby regulating leukocyte adhesion, transendothelial migration, and cytoskeletal reorganization. The knockout model disrupts these interactions, impairing downstream signaling and leukocyte binding, which is expected to attenuate inflammatory responses and potentially reduce metastatic dissemination.
In the CAL-27 background, ICAM1 plays a pivotal role in mediating adhesion to immune cells and components of the extracellular matrix, linking inflammatory signaling to cancer cell behavior. Disruption of ICAM1 is anticipated to compromise the ability of these malignant cells to engage with lymphocytes and endothelial surfaces, thereby affecting processes such as immune surveillance evasion, extravasation, and colonization at secondary sites. This knockout model thus provides a valuable tool for dissecting the contribution of ICAM1 to the pro-metastatic phenotype of oral squamous cell carcinoma, particularly in the context of NF-??B-driven inflammation and integrin-dependent signaling.
Researchers can utilize these ICAM1 knockout polyclonal cells in a variety of experimental paradigms. Flow cytometry enables verification of ICAM1 loss and quantification of surface integrin ligands, while adhesion assays with immobilized LFA-1 or Mac-1 directly measure functional binding capacity. Transwell migration assays assess the impact on cell motility and invasiveness, and Western blotting for phosphorylated Src and ERK1/2 reveals alterations in downstream signaling. Immunofluorescence can visualize changes in adhesion complex formation and cytoskeletal architecture. These applications make the product suitable for studies of tumor-immune interactions, inflammatory signaling networks, and metastasis biology. For further technical details and custom inquiries, please contact Ascent Research.
